Metabolic lipid muscle disorders: biomarkers and treatment

Lipid storage myopathies (LSMs) are metabolic disorders of the utilization of fat\r\nin muscles due to several different defects. In this review, a molecular update of LSMs is presented and recent attempts of finding treatment options are discussed.\r\nThe main topics discussed are: primary carnitine deficiency, riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency, neutral lipid storage disorders and carnitine palmitoyl transferase deficiency. The most frequent presentations and genetic abnormalities are summarized. We present their diagnosis utilizing biomedical and morphological biomarkers and possible therapeutic interventions. The treatment of these metabolic disorders is a subject of active translational research but appears, in some cases, still elusive.